Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 816

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model

Open access
Beck, Bo Ram, Shin, Bonggun, Choi, Yoonjung, Park, Sungsoo, Kang, Keunsoo · 2020 · Computational and Structural Biotechnology Journal

Published version of a preprint

Abstract

The infection of a novel coronavirus found in Wuhan of China (2019-nCoV) is rapidly spreading, and the incidence rate is increasing worldwide. Due to the lack of effective treatment options for 2019-nCoV, various strategies are being tested in China, including drug repurposing. In this study, we used our pretrained deep learning-based drug-target interaction model called Molecule Transformer-Drug Target Interaction (MT-DTI) to identify commercially available drugs that could act on viral proteins of 2019-nCoV. The result showed that atazanavir, an antiretroviral medication used to treat and prevent the human immunodeficiency virus (HIV), is the best chemical compound, showing a inhibitory potency with K d of 94.94 nM against the 2019-nCoV 3C-like proteinase, followed by efavirenz (199.17 nM), ritonavir (204.05 nM), and dolutegravir (336.91 nM). Interestingly, lopinavir, ritonavir, and darunavir are all designed to target viral proteinases. However, in our prediction, they may also bind to the replication complex components of 2019-nCoV with an inhibitory potency with K d < 1000 nM. In addition, we also found that several antiviral agents, such as Kaletra, could be used for the treatment of 2019-nCoV, although there is no real-world evidence supporting the prediction. Overall, we suggest that the list of antiviral drugs identified by the MT-DTI model should be considered, when establishing effective treatment strategies for 2019-nCoV.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.csbj.2020.03.025

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 4

  1. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M. et al: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; .
  2. Z. Jin X. Du Y. Xu Y. Deng M. Liu Z. Zhao et al. Structure of Mpro from COVID-19 virus and discovery of its inhibitors. bioRxiv. 2020.
  3. Dayer M.R., Taleb-Gassabi S. and Dayer M.S.: Lopinavir; a potent drug against coronavirus infection: insight from molecular docking study. Arch Clin Infect Diseas 2017; 12: e13823. · doi:10.5812/archcid.13823
  4. Hopkins J.S.U.S.: drugmakers ship therapies to China, seeking to treat coronavirus. Wall Street J 2020; .

Cited by

See all 816

Metadata

Authors
Beck, B. R., Shin, B., Choi, Y., Park, S., & Kang, K.
Venue
Computational and Structural Biotechnology Journal
Published
2020
Volume
18
Pages
784-790
ISSN
2001-0370 (ISSN-L)
OpenAlex
W3012994592
Cited by
816
References
32
FWCI
83.02
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.